GRTS - Gritstone Oncology (GRTS) on go with Phase 1 trial of COVID-19 vaccine shares up 34%

Gritstone Oncology (GRTS) jumps 34% premarket in reaction to advancing development of a second generation vaccine against SARS-CoV-2, with potential for both prolonged protection and potency against Spike mutants.The company and the National Institute of Allergy and Infectious Diseases ((NIAID)) have entered into a clinical trial agreement to initiate clinical testing. A Phase 1 trial is in development. Gritstone has access to validated SARS-CoV-2 epitopes that have been identified through studies of patients recovering from COVID-19. Using these epitopes and its Gritstone EDGE and vaccine platform technologies, GRTS is developing a novel vaccine against COVID-19, containing Spike but also additional viral epitopes that offer good targets for T cell immunity. The company uses both self-amplifying mRNA and adenoviral vectors to deliver the SARS-CoV-2 viral antigens. “Gritstone’s vaccine may provide more comprehensive viral protection by inducing a better combination of T cell responses and neutralizing antibodies as compared to the currently available vaccines,” said

For further details see:

Gritstone Oncology (GRTS) on go with Phase 1 trial of COVID-19 vaccine, shares up 34%